Cellectar Biosciences reports strong 12-month Phase 2b data for iopofosine I 131 in Waldenström Macroglobulinemia.

Cellectar Biosciences announced positive 12-month follow-up results from its Phase 2b CLOVER WaM trial of iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia, showing an 83.6% overall response rate and median response duration of 17.8 months. The data meet FDA requirements for accelerated approval and support a confirmatory trial planned for late 2026. The drug showed strong efficacy in patients previously treated with BTK inhibitors, a difficult-to-treat group, and maintained a manageable safety profile. This progress positions iopofosine I 131 as a promising new treatment option for heavily pretreated WM patients with limited alternatives.